Takeaways from the CMD, reiterate BUY rating ahead of key catalyst in 2024
Egetis hosted its CMD yesterday featuring i) a KOL presentation on MCT8 deficiency and its unmet need, ii) an update on the ReTRIACT pivotal trial, iii) Emcitate pre-commercial activities and iv) details on the next potential indication for Emcitate - resistance to thyroid hormone beta. ConcerningPledPharma AB is a Sweden-based biopharmaceutical company engaged in the development of treatments that increase the effectiveness of therapies for severe life threatening diseases. The Company's main focus is on the use of PLED-derivatives in supportive care based on an initial candidate, PP-095 for oncology and PP-099 for cardiology. PP-095 protects normal cells during cancer therapy with cytostatic/cytotoxic drugs, without diminishing the anticancer efficacy, while PP-099 has the potential to reduce the infarct size in connection with reperfusion of an acute myocardial infarct with percutaneous coronary intervention (PCI). PLED-derivatives also have potential indications for other oxidative stress related conditions, such as paracetamol (acetaminophen) - induced liver toxicity, iron and copper overload. As of May 2013, the Company was no longer majority owned by Accelerator Nordic AB (publ).
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.